These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1203 related items for PubMed ID: 20648928

  • 1. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P, Rumyantsev V.
    Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR.
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [Abstract] [Full Text] [Related]

  • 4. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Bailie GR, Mason NA, Valaoras TG.
    Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY.
    Arzneimittelforschung; 2010 Jan; 60(6a):399-412. PubMed ID: 20648931
    [Abstract] [Full Text] [Related]

  • 6. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U.
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [Abstract] [Full Text] [Related]

  • 7. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A, Mircescu G.
    Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia.
    Ikuta K, Shimura A, Terauchi M, Yoshii K, Kawabata Y.
    Int J Hematol; 2018 May; 107(5):519-527. PubMed ID: 29357079
    [Abstract] [Full Text] [Related]

  • 9. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
    Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
    [Abstract] [Full Text] [Related]

  • 10. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA, Hyppa A, Chuang A, Hanna F, Wilson E, Kwok C, Yan C, Gray Z, Mathew R, Falloon P, Dennis A, Pavlov T, Allen JC.
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [Abstract] [Full Text] [Related]

  • 11. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB.
    Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, Barish C, Bhaskar BS, Smith-Nguyen GN, Butcher A, Koch TA, Goodnough LT.
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [Abstract] [Full Text] [Related]

  • 13. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
    Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C, FERGI Study Group.
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
    [Abstract] [Full Text] [Related]

  • 14. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C.
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [Abstract] [Full Text] [Related]

  • 15. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D, Speed J, Medve R, Andrews JS.
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [Abstract] [Full Text] [Related]

  • 16. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA, Keating GM.
    Drugs; 2009 Jan; 69(6):739-56. PubMed ID: 19405553
    [Abstract] [Full Text] [Related]

  • 17. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F, Löhr B, Laubender RP, Tillack C, Schnitzler F, Breiteneicher S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.
    Digestion; 2012 Jan; 85(1):47-54. PubMed ID: 22179489
    [Abstract] [Full Text] [Related]

  • 18. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group.
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [Abstract] [Full Text] [Related]

  • 19. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.